|
Video: What is a Stock Split?
|
|
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe, rare muscle disorders. Co.'s primary product candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. Using its proprietary drug discovery platform, Co. is developing a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a range of genetically defined muscle disorders. According to our Edgewise Therapeutics stock split history records, Edgewise Therapeutics has had 0 splits. | |
|
Edgewise Therapeutics (EWTX) has 0 splits in our Edgewise Therapeutics stock split history database.
Looking at the Edgewise Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Edgewise Therapeutics shares, starting with a $10,000 purchase of EWTX, presented on a split-history-adjusted basis factoring in the complete Edgewise Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/29/2021 |
|
End date: |
04/25/2024 |
|
Start price/share: |
$35.99 |
|
End price/share: |
$15.94 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-55.71% |
|
Average Annual Total Return: |
-23.26% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$4,428.38 |
|
Years: |
3.08 |
|
|
|
|
|